Resistance of propionibacteria to antibiotics used in the treatment of acne

Brown, Jacqueline Marie; Poston, S. M.

doi:10.1099/00222615-16-3-271

Cited by 23 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one of these studies, clindamycin resistance emerged in 60% of strains of cutaneous flora (staphylococci, enterococci) [17] . Table 1 illustrates the in vitro antimicrobial activity of clindamycin (and erythromycin, where appropriate) against propionibacteria over time (1976 -2001) [18][19][20][21][22][23][24][25][26][27][28][29] . It should be noted that the susceptibility of propionibacteria to clindamycin appears to have fallen over this 25-year time period.…”

Section: Pharmacologymentioning

confidence: 99%

Topical clindamycin in the management of acne vulgaris

Guay

2007

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

A small cadre of antimicrobials are commonly used and regarded as effective and safe, as systemic and topical treatments of acne vulgaris. These include oral tetracycline, doxycycline, minocycline and topical clindamycin and erythromycin. Topical antimicrobials work via both antimicrobial and non-antimicrobial mechanisms: the former due to suppression of the growth of propionibacterial species (especially Propionibacterium acnes and P. granulosum). Clindamycin appears to be superior in efficacy compared with erythromycin and tetracycline. However, the emergence and spread of resistance among propionibacteria to both erythromycin and clindamycin calls into question their long-term viability as topical anti-acne therapies. Only through judicious use of combination topical therapies (e.g., topical retinoid, benzoyl peroxide or azelaic acid plus clindamycin or erythromycin) and the practice of effective infection control (i.e., handwashing between seeing patients in the clinic) can both clindamycin's and erythromycin's widespread utility be preserved in this disorder.

show abstract

Section: Pharmacologymentioning

confidence: 99%

Topical clindamycin in the management of acne vulgaris

Guay

2007

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…In this context, one crucial point to consider is that for the past 30 years, the percentage of acne patients carrying P. acnes strains resistant to erythromycin and tetracycline is increasing 3,4 . Furthermore, a link between the presence of P. acnes resistant strains and clinical unresponsiveness or a greater frequency of relapses has been demonstrated with erythromycin, 4 but also with the cyclines 5 .…”

Section: Introductionmentioning

confidence: 99%

Bacterial resistance in French acne patients

Dumont-Wallon

Moyse²,

Blouin

et al. 2010

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Antibiotics erythromycin (E), clindamycin (C), and tetracycline (T) were added to the basal medium at the following concentrations: erythromycin (TYEg-E) (0.5 μg mL -1 ), clindamycin (TYEg-C) (0.5 μg mL -1 ), and tetracycline (TYEg-T) (5 μg mL -1 ) (Brown and Poston, 1983; Eady E.A. et al, 2003; Ross et al, 2003).…”

Section: Methodsmentioning

confidence: 99%

Non-antibiotic Isotretinoin Treatment Differentially Controls Propionibacterium acnes on Skin of Acne Patients

et al. 2017

View full text Add to dashboard Cite

Emergence and potential transfer of antibiotic resistance in skin microorganisms is of current concern in medicine especially in dermatology contexts where long term treatment with antibiotics is common. Remarkably, non-antibiotic therapy in the form of isotretinoin – a non-antimicrobial retinoid is effective at reducing or eradicating the anaerobe Propionibacterium acnes which is causally involved in the complex pathogenesis of Acne vulgaris. This study measured the extent of colonization of P. acnes in patients with primary cystic or severe acne from three defined skin sites in ‘non-lesion’ areas before, during and after treatment with isotretinoin. Patients attending acne clinics were investigated using standardized skin sampling techniques and the recovery of anaerobic P. acnes from 56 patients comprising 24 females and 32 males (mean age 22 years, age range 15–46 years) who were given a standard course of isotretinoin (1 mg/kg/day) are reported. P. acnes cultured from the external cheek surface of patients following treatment showed a significant reduction (1–2 orders of magnitude) compared with their pre-treatment status. Interestingly, other distinct sites (nares and toe web) failed to show this reduction. In addition, high levels of antibiotic-resistant P. acnes were recorded in each patients’ skin microbiota before, during and after treatment. In this study, microbial composition of the skin appears substantially altered by isotretinoin treatment, which clearly has differential antimicrobial effects on each anatomically distinct site. Our study confirmed that orally administered isotretinoin shows good efficacy in the resolution of moderate to severe acne that correlates with reductions in the number of P. acnes on the skin, including resistant isolates potentially acquired from previous treatments with antibiotics. Our study suggests that the role of tetracycline’s and macrolides, which are currently first line treatments in dermatology, might be reserved for severe or life-threatening infections since current antibiotic stewardship guidelines from medical departments no longer prescribe these antibiotics for routine use.

show abstract

Resistance of propionibacteria to antibiotics used in the treatment of acne

Cited by 23 publications

References 37 publications

Topical clindamycin in the management of acne vulgaris

Topical clindamycin in the management of acne vulgaris

Bacterial resistance in French acne patients

Non-antibiotic Isotretinoin Treatment Differentially Controls Propionibacterium acnes on Skin of Acne Patients

Contact Info

Product

Resources

About